The Cellular Response to Oxidatively Induced DNA Damage and Polymorphism of Some DNA Repair Genes Associated with Clinicopathological Features of Bladder Cancer

Table 6

Distribution of allelic variants of some DNA repair genes in the group of BC patients as compared to controls.

Genotypes/variant alleles	BC cases		Controls
		%		%
ERCC2/XPD Lys751Gln (rs13181)
Lys/Lys	120	29.2	132	36.2^a	0.039
Lys/Gln	212	51.6	160	43.8^b	0.031
Gln/Gln	79	19.2	73	20.0	>0.05
Lys/Gln + Gln/Gln	291	70.8	233	63.8^c	0.039
Gln	370/822	45.0	306/730	41.9	>0.05
ERCC6/CSB Gly399Asp (rs2228528)
Gly/Gly	283	68.0	259	71.0	>0.05
Gly/Asp	121	29.1	101	27.7	>0.05
Asp/Asp	12	2.9	5	1.4	>0.05
Gly/Asp + Asp/Asp	133	32.0	106	29.0	>0.05
Asp	145/832	17.4	111/730	15.2	>0.05

The genotypic distribution is in accordance with Hardy-Weinberg equilibrium in the control and case groups: = 3.63 and 0.72 ( = 0.06 and 0.39) for ERCC2/XPD Lys751Gln polymorphism; = 1.95 and 0.05 ( = 0.16 and 0.83) for ERCC6/CSB Gly399Asp polymorphism.
OR [95% CI] = 0.73 [0.54–0.98], = 0.039; ^bOR [95% CI] = 1.36 [1.03–1.81], = 0.031; ^cOR [95% CI] = 1.37 [1.02–1.86], = 0.039. OR values describe a homozygous wild type genotype of the XPD gene as a protective factor, whereas the heterozygous genotype and sum of genotypes containing a variant allele seem to be risk factors for developing bladder cancer.